Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary Background Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease. Methods Data from the comparator arms of four phase 3 clinical trials in first-line metastatic castration-resistant prostate cancer were obtained from Project Data Sphere, comprising 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE trial, and 470 patients treated with docetaxel and placebo in the ENTHUSE 33 trial. Datasets consisting of more than 150 clinical variables were curated centrally, including demographics, laboratory values, medical history, lesion sites, and previous treatments. Data from ASCENT2, MAINSAIL, and VENICE were released publicly to be used as training data to predict the outcome of interest—namely, overall survival. Clinical data were also released for ENTHUSE 33, but data for outcome variables (overall survival and event status) were hidden from the challenge participants so that ENTHUSE 33 could be used for independent validation. Methods were evaluated using the integrated time-dependent area under the curve (iAUC). The reference model, based on eight clinical variables and a penalised Cox proportional-hazards model, was used to compare method performance. Further validation was done using data from a fifth trial—ENTHUSE M1—in which 266 patients with metastatic castration-resistant prostate cancer were treated with placebo alone. Findings 50 independent methods were developed to predict overall survival and were evaluated through the DREAM challenge. The top performer was based on an ensemble of penalised Cox regression models (ePCR), which uniquely identified predictive interaction effects with immune biomarkers and markers of hepatic and renal function. Overall, ePCR outperformed all other methods (iAUC 0·791; Bayes factor >5) and surpassed the reference model (iAUC 0·743; Bayes factor >20). Both the ePCR model and reference models stratified patients in the ENTHUSE 33 trial into high-risk and low-risk groups with significantly different overall survival (ePCR: hazard ratio 3·32, 95% CI 2·39–4·62, p<0·0001; reference model: 2·56, 1·85–3·53, p<0·0001). The new model was validated further on the ENTHUSE M1 cohort with similarly high performance (iAUC 0·768). Meta-analysis across all methods confirmed previously identified predictive clinical variables and revealed aspartate aminotransferase as an important, albeit previously under-reported, prognostic biomarker. Interpretation Novel prognostic factors were delineated, and the assessment of 50 methods developed by independent international teams establishes a benchmark for development of methods in the future. The results of this effort show that data-sharing, when combined with a crowdsourced challenge, is a robust and powerful framework to develop new prognostic models in advanced prostate cancer. Funding Sanofi US Services, Project Data Sphere.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationGenomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationLongo, D. L., & Drazen, J. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1516564 · Cited by 419
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
Self-citation
Cited by
CHAOS Challenge - combined (CT-MR) healthy abdominal organ segmentation
Kavur, A. E., Gezer, N. S., Barış, M., Aslan, S., Conze, P.-H., Groza, V., Pham, D. D., Chatterjee, S., Ernst, P., Özkan, S., et al. (2021) · Medical Image Analysis · doi:10.1016/j.media.2020.101950 · Cited by 815
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Self-citationWells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538
Self-citationIoannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175
Bonifacio, E., Beyerlein, A., Hippich, M., Winkler, C., Vehik, K., Weedon, M. N., Laimighofer, M., Hattersley, A. T., Krumsiek, J., Frohnert, B. I., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002548 · Cited by 148
Metadata
- Authors
- Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., Peddinti, G., Airola, A., Pahikkala, T., Mirtti, T., Yu, T., Bot, B. M., Shen, L., Abdallah, K., Norman, T., Friend, S., Stolovitzky, G., Soule, H., Sweeney, C. J., Ryan, C. J., Scher, H. I., Sartor, O., Xie, Y., Aittokallio, T., Zhou, F. L., Costello, J. C., Abdallah, K., Aittokallio, T., Airola, A., Anghe, C., Azima, H., Baertsch, R., Ballester, P. J., Bare, C., Bhandari, V., Bot, B. M., Dang, C. C., Dunbar, M. B.-N., Buchardt, A.-S., Buturovic, L., Cao, D., Chalise, P., Cho, J., Chu, T.-M., Coley, R. Y., Conjeti, S., Correia, S., Costello, J. C., Dai, Z., Dai, J., Dargatz, P., Delavarkhan, S., Deng, D., Dhanik, A., Du, Y., Elangovan, A., Ellis, S., Elo, L. L., Espiritu, S. M., Fan, F., Farshi, A. B., Freitas, A., Fridley, B., Friend, S., Fuchs, C., Gofer, E., Peddinti, G., Graw, S., Greiner, R., Guan, Y., Guinney, J., Guo, J., Gupta, P., Guyer, A. I., Han, J., Hansen, N. R., Chang, B. H., Hirvonen, O., Huang, B., Huang, C., Hwang, J., Ibrahim, J. G., Jayaswa, V., Jeon, J., Ji, Z., Juvvadi, D., Jyrkkiö, S., Kanigel-Winner, K., Katouzian, A., Kazanov, M. D., Khan, S. A., Khayyer, S., Kim, D., Golinska, A. K., Koestler, D., Kokowicz, F., Kondofersky, I., Krautenbacher, N., Krstajic, D., Kumar, L., Kurz, C., Kyan, M., Laajala, T. D., Laimighofer, M., Lee, E., Lesinski, W., Li, M., Li, Y., Lian, Q., Liang, X., Lim, M., Lin, H., Lin, X., Lu, J., Mahmoudian, M., Manshaei, R., Meier, R., Miljkovic, D., Mirtti, T., Mnich, K., Navab, N., Neto, E. C., Newton, Y., Norman, T., Pahikkala, T., Pal, S., Park, B., Patel, J., Pathak, S., Pattin, A., Ankerst, D. P., Peng, J., Petersen, A. H., Philip, R., Piccolo, S. R., Pölsterl, S., Polewko-Klim, A., Rao, K., Ren, X., Rocha, M., Rudnicki, W. R., Ryan, C. J., Ryu, H., Sartor, O., Scherb, H., Sehgal, R., Seyednasrollah, F., Shang, J., Shao, B., Shen, L., Sher, H., Shiga, M., Sokolov, A., Söllner, J. F., Song, L., Soule, H., Stolovitzky, G., Stuart, J., Sun, R., Sweeney, C. J., Tahmasebi, N., Tan, K.-T., Tomaziu, L., Usset, J., Vang, Y. S., Vega, R., Vieira, V., Wang, D., Wang, D., Wang, J., Wang, L., Wang, S., Wang, T., Wang, Y., Wolfinger, R., Wong, C., Wu, Z., Xiao, J., Xie, X., Xie, Y., Xin, D., Yang, H., Yu, N., Yu, T., Yu, X., Zahedi, S., Zanin, M., Zhang, C., Zhang, J., Zhang, S., Zhang, Y., Zhou, F. L., Zhu, H., Zhu, S., & Zhu, Y.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 18
- Issue
- 1
- Pages
- 132-142
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2552908002
- Cited by
- 135
- References
- 9
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30560-5
- The paper
- Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., Peddinti, G., Airola, A., Pahikkala, T., Mirtti, T., Yu, T., Bot, B. M., Shen, L., Abdallah, K., Norman, T., Friend, S., Stolovitzky, G., Soule, H., . . . Zhu, Y. (2017). Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30560-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.